Mr. Michal Efraty reports

NEUROTHERA LABS ANNOUNCES ISRAELI PATENT APPLICATION IN COLLABORATION WITH CLEARMIND MEDICINE FOR NOVEL NON-HALLUCINOGENIC NEUROPLASTOGEN TREATMENT FOR DEPRESSION

Neurothera Labs Inc. has noted that Clearmind Medicine Inc. (Nasdaq: CMND) has filed an Israeli patent application for an innovative combination therapy of 5-methoxy-2-aminoindane (MEAI) and N-Acylethanolamines, such as Palmitoylethanolamide (PEA), addressing depression.

The patent application results from the continuing collaboration between Neurothera and Clearmind Medicine. This therapy targets depression treatment using the combination of MEAI and PEA. According to the World Health Organization, major depressive disorder affects more than 280 million people worldwide and remains one of the leading causes of disability, with limited innovative treatment options available.

This new filing further expands the joint intellectual property portfolio developed through the collaboration. To date, 13 patents have been filed under the partnership, focusing on MEAI and N-Acylethanolamines combinations for conditions such as alcohol use disorder, cocaine addiction, obesity and weight loss, and depression. Preclinical data supports MEAI's efficacy in mitigating addictive behaviors while preserving normal natural reward pathways.

About Neurothera Labs Inc.

Neurothera Labs is a clinical-stage pharmaceutical company focused on developing novel therapeutics for central nervous system disorders and other underserved health conditions through collaborations and innovative combinations.

We seek Safe Harbor.